The relevance of the bleeding severity in the treatment of acquired haemophilia - an update of a single-centre experience with 67 patients (original) (raw)

Acquired haemophilia (AH) is a bleeding disorder characterized by autoantibodies against coagulation factors, leading to variable bleeding severity. This study presents the clinical and laboratory data from 67 AH patients treated in a single-center, emphasizing the modified Bonn-Malmö protocol (MBMP) for severe cases. The findings suggest a tailored treatment approach based on bleeding severity, demonstrating that while AH is a curable condition, treatment costs and long-term outcomes vary considerably.